Solvay

07/11/19 -"We have made some adjustments to take into account the huge impairment and added some first costs (€120m for 2019-21) in the implementation of the €300-350m cost reduction plan to our P&L. "

PDF page sample
Pages
59
Language
English
Published on
07/11/19
Download
You may also be interested by these reports :
31/10/25
Wacker delivered mixed Q3 2025 results as weak demand and prices – partly a consequence of Chinese oversupply – weighed on sales. While EBITDA beat ...
30/10/25
Clariant’s Q3 results remained soft on the back of industry-wide macroeconomic weakness. However, improved pricing and mix, along with cost-side ...
30/10/25
DSM has fallen short of expectations, delivering organic revenue growth at 2%, while the consensus was expecting 50bps more. Despite this, the EBITDA ...
30/10/25
3Q25 EBITDA 5% above consensus – FY25 guidance confirmed

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO